OR WAIT null SECS
Ajinomoto and its subsidiary company, Ajinomoto Genexine, have partnered with Insilico Biotechnology to accelerate and improve process development and production of biologics using digital twin technology.
An agreement has been reached between Ajinomoto and its subsidiary company, Ajinomoto Genexine, and Insilico Biotechnology aimed at accelerating and improving process development and production of biologics using digital twin technology.
According to an Oct. 26, 2021 press release, the companies will employ Insilico’s digital twins technology and Ajinomoto’s cell-culture media platform to speed up and improve the development of cell culture processes. Through the joint offering, Ajinomoto Genexine expects to meet the rising demand for cell culture media in the Asia Pacific region (APAC).
“We have found a wonderful partner in Ajinomoto. Their strength is in developing and producing quality media quickly, whereas our strength lies in fast and superior optimization of media compositions including the feeding strategy,” said Klaus Mauch, CEO of Insilico, in the press release. “Together, we can offer rapid process development to existing and new customers.”
“Biomanufacturing in the APAC region has unique needs. Aggressive timelines are one aspect,” added Yuta Nakai, president of Ajinomoto Genexine, in the press release. “With Insilico’s Digital Twins plugged into our high-quality media development technology, we aim to shorten timelines by up to 50%. We will continue to fine tune our offerings based on our customers’ voice.”
“This collaboration excites me because it makes digitalization accessible to a larger number of customers in the APAC region,” said Shilpa Nargund, director of Insilico’s APAC operations, in the press release. “The Digital Twins ability to virtually screen media together with Ajinomoto’s quick turnaround on media production give customers the option to test tailored media for their cell lines and clones.”
Source: Insilico Biotechnology